|  | Cancer | Lymphoma

Blastoma: Cancers from Embryonic Cells—Types, Diagnosis & Treatment

What Is a Blastoma?

Blastoma is a malignant tumor arising from immature precursor cells (blasts) during embryonic or fetal development. The suffix "-blastoma" indicates cell origin (e.g., neuroblast → neuroblastoma). These are predominantly **pediatric cancers**.

Major Types

BlastomaCell OriginTypical AgePrimary SiteKey Features
MedulloblastomaNeural precursorsChildren (3–8 yrs)Cerebellum (posterior fossa)Most common malignant pediatric brain tumor; spreads via CSF
NeuroblastomaSympathetic neuroblastsInfants/young childrenAdrenal gland, abdomen, chestVariable behavior: spontaneous regression to aggressive metastasis; MYCN amplification = poor prognosis
RetinoblastomaRetinal precursors<5 yearsRetinaHeritable (RB1 germline) or sporadic; leukocoria (white pupil) hallmark
Nephroblastoma (Wilms Tumor)Renal blastema2–5 yearsKidneyMost common pediatric renal cancer; associated with WAGR, Beckwith-Wiedemann syndromes
HepatoblastomaHepatic precursors<3 yearsLiverMost common pediatric liver cancer; AFP tumor marker
Germ Cell TumorsPrimordial germ cellsChildren & young adultsGonads (testis/ovary), sacrococcygeal, mediastinumSeminoma, yolk sac tumor, teratoma; AFP/β-hCG markers
Pleuropulmonary BlastomaLung mesenchymalYoung childrenLung/pleuraRare; associated with DICER1 mutation

Diagnosis

  • Imaging: MRI (brain), CT/US (abdomen), PET-CT (staging)
  • Biopsy: Histopathology + immunohistochemistry
  • Molecular: MYCN, RB1, CTNNB1, DICER1, etc.
  • Markers: AFP, β-hCG, NSE, LDH
  • Bone marrow aspirate/biopsy (neuroblastoma, germ cell)
  • Lumbar puncture (medulloblastoma, retinoblastoma)

Treatment: Multimodal & Risk-Adapted

  • Surgery: Resection (goal: gross total); biopsy if unresectable.
  • Chemotherapy: Multi-agent protocols (e.g., COG, SIOP, GPOH); neoadjuvant or adjuvant.
  • Radiation: For residual/local control; proton therapy reduces late effects.
  • High-dose chemo + stem cell rescue: High-risk neuroblastoma, germ cell.
  • Targeted/Immunotherapy: Anti-GD2 (dinutuximab) for neuroblastoma; checkpoint inhibitors in trials.

Prognosis & Survivorship

Varies dramatically by type, stage, molecular profile. Many have >80–90% cure rates (Wilms, low-risk neuroblastoma, retinoblastoma). Long-term follow-up essential for late effects: cardiotoxicity, neurocognitive, endocrine, second malignancies.

Lymphoma - Related Articles